Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology

Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology

Abstract INTRODUCTION This study evaluated the performance of the Lumipulse plasma beta‐amyloid (Aβ) 42/40 and pTau181 compared to other assays to detect an abnormal amyloid‐positron emission tomography (PET). METHODS Plasma samples from cognitively unimpaired (N = 179) and MCI/AD dementia (N = 36)...

Full description

Bibliographic Details
Main Authors:	Daniel J. Figdore, Heather J. Wiste, Joshua A. Bornhorst, Randall J. Bateman, Yan Li, Jonathan Graff‐Radford, David S. Knopman, Prashanthi Vemuri, Val J. Lowe, Clifford R. Jack Jr, Ronald C. Petersen, Alicia Algeciras‐Schimnich
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:	Alzheimer's disease blood biomarkers amyloid beta amyloid‐PET Aβ42/Aβ40 plasma pTau pTau181
Online Access:	https://doi.org/10.1002/dad2.12545

Similar Items

Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease
by: Tengfei Guo, et al.
Published: (2020-08-01)

An EWAS of dementia biomarkers and their associations with age, African ancestry, and PTSD
by: Mark W. Miller, et al.
Published: (2024-03-01)

The Expression of Cellular Prion Protein, PrPC, Favors pTau Propagation and Blocks NMDAR Signaling in Primary Cortical Neurons
by: Rafael Rivas-Santisteban, et al.
Published: (2023-01-01)

PtAu Nanoparticle as a Catalyst for Ethanol Electrooxidation
by: Amelia Sabella, et al.
Published: (2023-06-01)

Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment
by: Pia Kivisäkk, et al.
Published: (2023-03-01)

Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild traumatic brain injury
by: Ryan P. Bruhns, et al.
Published: (2022-08-01)

Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
by: Ching-Chi Hsu, et al.
Published: (2024-03-01)

Protective Effect of the Novel Melatonin Analogue Containing Donepezil Fragment on Memory Impairment via MT/ERK/CREB Signaling in the Hippocampus in a Rat Model of Pinealectomy and Subsequent Aβ<sub>1-42</sub> Infusion
by: Jana Tchekalarova, et al.
Published: (2024-02-01)

PtAu Nanoparticles Supported by Reduced Graphene Oxide as a Highly Active Catalyst for Hydrogen Evolution
by: Lazar Rakočević, et al.
Published: (2021-12-01)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
by: Josef Marksteiner, et al.
Published: (2022-09-01)

Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers
by: Hyuk Sung Kwon, et al.
Published: (2023-10-01)

Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum
by: Yi-He Chen, et al.
Published: (2022-06-01)

Dual regulatory effects of neferine on amyloid-β and tau aggregation studied by in silico, in vitro, and lab-on-a-chip technology
by: Yunkwon Nam, et al.
Published: (2024-03-01)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
by: Juan Lantero-Rodriguez, et al.
Published: (2023-03-01)

Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values
by: Eline A.J. Willemse, et al.
Published: (2017-01-01)

Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer’s Disease
by: Chiara Fornari, et al.
Published: (2022-04-01)

Diffusion tensor imaging (DTI) and plasma p-tau 181 in Alzheimer’s disease
by: Fardin Nabizadeh, et al.
Published: (2022-06-01)

Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis
by: Wenqi Cui, et al.
Published: (2022-10-01)

Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
by: Kaden L. Nystuen, et al.
Published: (2024-01-01)

New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease
by: Botond Penke, et al.
Published: (2023-03-01)

Correlation between cognitive impairment and serum phosphorylated tau181 protein in patients with preeclampsia
by: Yuanyuan Wang, et al.
Published: (2023-03-01)

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes
by: Chin-Hsien Lin, et al.
Published: (2018-04-01)

Semantic intrusion errors are associated with plasma Ptau-181 among persons with amnestic mild cognitive impairment who are amyloid positive
by: Rosie E. Curiel Cid, et al.
Published: (2023-08-01)

Fasudil reduces β-amyloid levels and neuronal apoptosis in APP/PS1 transgenic mice via inhibition of the Nogo-A/NgR/RhoA signaling axis
by: Min-Fang Guo, et al.
Published: (2020-12-01)

Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid
by: Maria-Salud eGarcía-Ayllón, et al.
Published: (2011-09-01)

Recent High-Resolution Structures of Amyloids Involved in Neurodegenerative Diseases
by: Rodrigo Diaz-Espinoza
Published: (2021-11-01)

Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease
by: Zhengshi Yang, et al.
Published: (2023-11-01)

Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease
by: Anniina Snellman, et al.
Published: (2023-07-01)

Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease
by: Yuanxin Zhao, et al.
Published: (2022-07-01)

High Cerebrospinal Fluid CX3CL1 Levels in Alzheimer’s Disease Patients but Not in Non-Alzheimer’s Disease Dementia
by: Giulia Bivona, et al.
Published: (2022-09-01)

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
by: Castillo-Carranza DL, et al.
Published: (2013-12-01)

Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model
by: Fernando Goñi, et al.
Published: (2018-01-01)

Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
by: Melissa E. Murray, et al.
Published: (2022-12-01)

Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease
by: Christopher A Brown, et al.
Published: (2017-01-01)

DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes
by: Bangfu Zhu, et al.
Published: (2022-07-01)

Anesthesia and surgery-induced elevation of CSF sTREM2 is associated with early cognitive dysfunction after thoracoabdominal aortic dissection surgery
by: Kexin Wang, et al.
Published: (2022-12-01)

Transmissibility versus Pathogenicity of Self-Propagating Protein Aggregates
by: Byron Caughey, et al.
Published: (2019-11-01)

Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
by: Roberta Cascella, et al.
Published: (2021-05-01)

The study of therapeutic efficacy and mechanisms of Schisandra chinensis and Evodia rutaecarpa combined treatment in a rat model of Alzheimer's disease
by: Qingyu Cao, et al.
Published: (2023-11-01)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
by: Christopher Clark, et al.
Published: (2021-03-01)